Within solid tumor targeted therapies, we are focused on discovering and developing transformative treatments for lung cancer, urothelial cancer (bladder cancer) and colorectal cancer.
We are committed to leading a paradigm shift in the treatment of lung cancer, the second most common cancer in both men and women. Our strategy involves targeting the complex nature of the disease by interfering with multiple disease mechanisms. This involves three distinct approaches: targeted therapy with small and large molecules, bi-specifics designed to affect two different targets, and vaccine-based therapy. Our focus includes non-small cell lung cancer (NSCLC), as well as small cell lung cancer. About 85 percent of lung cancers are NSCLC; the overall survival rate of patients diagnosed with NSCLC is 23 percent.
UROTHELIAL CANCER (BLADDER CANCER)
Despite available therapies, there is a high unmet need based on the prevalence of poor outcomes. We are focusing on better understanding the drivers of urothelial cancer so that we can leverage targeted therapies alone and in combination to improve outcomes. An estimated 550,000 new cases of bladder cancer worldwide were diagnosed in 2018 alone.
In colorectal cancer, we are exploring stem cell properties, including how they self-renew, and the related hypothesis that tumors are proliferated by a type of cancer stem cell. We are also pursuing ways to prevent and arrest the development of malignancies of the colon and rectum by diagnosing and treating precursor lesions. Colorectal cancer is the third leading cause of cancer deaths worldwide, with 1.8 million cases diagnosed worldwide in 2018.